Tag: ELAN
Gene Expression Profile Test IDs Patients Who Can Skip SLNB in Melanoma
Of patients identified as low risk by combined clinicopathological factors and GEP test, only 7.1 percent were SLN-positive
COVID Vaccine Before ICI Initiation Tied to Increased Survival in Patients With Cancer
SARS-CoV-2 mRNA vaccination within 100 days of ICI initiation was associated with increased overall survival in patients with NSCLC or metastatic melanoma
Recurrence-Free Survival Longer With Nivolumab Than Ipilimumab in Melanoma
Median duration of recurrence-free survival was 61.1 months with nivolumab and 24.2 months with ipilimumab
Higher Tattoo Exposure Linked to Reduced Melanoma Risk
Overall melanoma risk lower for those who had received four or more tattoo sessions, had three or more large tattoos
Low Metastasis Rate Seen for Radiation Plus Silicone Oil in Uveal Melanoma
In recent study, only 16 percent of patients developed metastases
High Response to PD-1 Therapy Seen in Unresectable Desmoplastic Melanoma
Complete response rate was 37 percent, and post-hoc end point of objective response rate was 89 percent
Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma
80 percent of adult patients with stage III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
Introduction of immune checkpoint inhibitors linked to widening disparity for those with private insurance versus those without insurance
AI Better for Tumor-Infiltrating Lymphocyte Quantification in Melanoma Than Traditional Methods
Machine learning algorithm has superior reproducibility and prognostic associations compared with traditional pathologist-read methods
Mismatch Repair Germline Pathogenic Variants Could Predispose to Uveal Melanoma
Twenty-one pathogenic variants found in clinically relevant genes, with an enrichment in mismatch repair genes
